tsc-203-a0201
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2023 (NCT05973487)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma · Phase 1
- Carcinoma · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Head and Neck Neoplasms · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Penile Neoplasms · Phase 1
- Rectal Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1
- Vulvar Neoplasms · Phase 1
Mechanism of action
- Melanoma antigen preferentially expressed in tumorsImmunity, passive
immunity, passive - PRAME
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05973487 | Phase 1 | Nov 30, 2023 | TScan Therapeutics, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TScan Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1